Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Approvable letter for Accretropin

March 13, 2007

FDA updates safety information for erythropoiesis-stimulating agents

March 13, 2007

Sym-001, first recombinant polyclonal antibody to enter clinical trials

March 13, 2007

TM-30339 advanced into clinical trials for obesity

March 13, 2007

Formulation work required for CRD-5 following phase I/II findings

March 13, 2007

Recent IRM patent describes new treatment option for thrombocytopenia

March 12, 2007

Phase III planned for Diamyd in type 1 diabetes

March 12, 2007

Orphan Europe acquires rights to Cystadane

March 12, 2007

Lipitor approved for five new indications in heart disease

March 8, 2007

Target enrollment reached in phase III trials of Puricase

March 8, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...